TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05722275

Intervention type: DIAGNOSTIC_TEST
Intervention: Peritoneal metastasis status ascertainment
Description: Each participant with gastric cancer will undergo enhanced CT examination for detection of peritoneal metastasis. Within two weeks of CT examination, the participant will undergo diagnostic laparoscopy to confirm the status of peritoneal metastasis.

Intervention type: DIAGNOSTIC_TEST
Intervention: Peritoneal metastasis status ascertainment
Description: Each participant with gastric cancer will undergo enhanced CT examination for detection of peritoneal metastasis. Within two weeks of CT examination, the participant will undergo diagnostic laparoscopy to confirm the status of peritoneal metastasis.

Intervention type: DIAGNOSTIC_TEST
Intervention: Peritoneal metastasis status ascertainment
Description: Each participant with gastric cancer will undergo enhanced CT examination for detection of peritoneal metastasis. Within two weeks of CT examination, the participant will undergo diagnostic laparoscopy to confirm the status of peritoneal metastasis.

Intervention type: DIAGNOSTIC_TEST
Intervention: Peritoneal metastasis status ascertainment
Description: Each participant with gastric cancer will undergo enhanced CT examination for detection of peritoneal metastasis. Within two weeks of CT examination, the participant will undergo diagnostic laparoscopy to confirm the status of peritoneal metastasis.

Intervention type: DIAGNOSTIC_TEST
Intervention: Peritoneal metastasis status ascertainment
Description: Each participant with gastric cancer will undergo enhanced CT examination for detection of peritoneal metastasis. Within two weeks of CT examination, the participant will undergo diagnostic laparoscopy to confirm the status of peritoneal metastasis.

Intervention type: DIAGNOSTIC_TEST
Intervention: Peritoneal metastasis status ascertainment
Description: Each participant with gastric cancer will undergo enhanced CT examination for detection of peritoneal metastasis. Within two weeks of CT examination, the participant will undergo diagnostic laparoscopy to confirm the status of peritoneal metastasis.
Study: NCT04067115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabectedin 1 MG [Yondelis]
Description: Patients with Ewing sarcoma will be administered trabectedin intravenously. Cycles are 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Patients with Ewing sarcoma will be administered inirotecan intravenously. Cycles are 21 days.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: tumor biopsy
Description: Tumor tissue samples will be collected collected at two timepoints. The first biopsy will be prior to treatment. If a biopsy is not possible archival tissue may be submitted. A second tumor biopsy will be taken fro consenting patients when possible after the first administration of Trabectedin to evaluate the effect on the tumor cells.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3'-Deoxy-3'-18F Fluorothymidine (18F-FLT) Imaging
Description: Some patients will receive PET scans with the use of 18F-FLT, a radioactive tracer, performed at the National Institute of Health.
Study: NCT06046638

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Induction of anesthesia followed by continuous infusion through out surgery. The anesthetic drug regimen will be adjusted according to the changes of blood pressure.
Study: NCT06355271

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl 1
Description: Spinal anesthesia with a 27- gauge Whitacre needle at the L2-3 or L3-4 intervertebral space with the patient in sitting position with hyperbaric bupivacaine 0,5 %12 mg, 100 mcg of morphine, and no fentanyl

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fentanyl2
Description: Spinal anesthesia with a 27- gauge Whitacre needle at the L2-3 or L3-4 intervertebral space with the patient in sitting position with hyperbaric bupivacaine 0,5 %12 mg, 100 mcg of morphine, and 10 mcg of of fentanyl

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fentanyl 3
Description: Spinal anesthesia with a 27- gauge Whitacre needle at the L2-3 or L3-4 intervertebral space with the patient in sitting position with hyperbaric bupivacaine 0,5 %12 mg, 100 mcg of morphine, and 20 mcg of fentanyl
Study: NCT06552897

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Intervention 1: Adductor Canal Block (ACB)
Description: For the Interventions section, you should describe the specific procedures or treatments administered in each arm of your study. Here's how you might present the interventions:~Intervention 1: Adductor Canal Block (ACB) Name: Adductor Canal Block (ACB) Type: Procedure~Description:~Participants receive an ultrasound-guided adductor canal block. Dose and Administration: 20 ml of 0.25% bupivacaine is injected to target the saphenous nerve within the adductor canal.~Objective: To provide analgesia to the anterior and medial aspects of the knee, preserving motor function to facilitate early mobilization.
Study: NCT05722275

Intervention type: DIAGNOSTIC_TEST
Intervention: Peritoneal metastasis status ascertainment
Description: Each participant with gastric cancer will undergo enhanced CT examination for detection of peritoneal metastasis. Within two weeks of CT examination, the participant will undergo diagnostic laparoscopy to confirm the status of peritoneal metastasis.

Intervention type: DIAGNOSTIC_TEST
Intervention: Peritoneal metastasis status ascertainment
Description: Each participant with gastric cancer will undergo enhanced CT examination for detection of peritoneal metastasis. Within two weeks of CT examination, the participant will undergo diagnostic laparoscopy to confirm the status of peritoneal metastasis.

Intervention type: DIAGNOSTIC_TEST
Intervention: Peritoneal metastasis status ascertainment
Description: Each participant with gastric cancer will undergo enhanced CT examination for detection of peritoneal metastasis. Within two weeks of CT examination, the participant will undergo diagnostic laparoscopy to confirm the status of peritoneal metastasis.
Study: NCT05446350

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transcranial alternating current stimulation (tACS)
Description: transcranial alternating current stimulation (tACS) used to manipulate how neural activity aligns to speech rhythm, leading to changes in speech perception

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transcranial alternating current stimulation (tACS)
Description: transcranial alternating current stimulation (tACS) used to manipulate how neural activity aligns to speech rhythm, leading to changes in speech perception

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transcranial alternating current stimulation (tACS)
Description: transcranial alternating current stimulation (tACS) used to manipulate how neural activity aligns to speech rhythm, leading to changes in speech perception

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transcranial alternating current stimulation (tACS)
Description: transcranial alternating current stimulation (tACS) used to manipulate how neural activity aligns to speech rhythm, leading to changes in speech perception

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: electroencephalography (EEG)
Description: analyse rhythmic electroencephalography responses that outlast the stimulation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: brain imaging (fMRI)
Description: Using brain imaging (fMRI) to predict optimal stimulation protocols for individual participants

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: electroencephalography (EEG) with neurofeedback
Description: Using neurofeedback to teach participants to enhance their own neural entrainment
Study: NCT05496725

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Micafungin
Description: Pharmacokinetic study under fasting conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micafungin
Description: Pharmacokinetic study under fasting conditions
Study: NCT06552897

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Intervention 2: Combined Adductor Canal Block and Selective Tibial Nerve Block (ACB + STNB)
Description: Name: Combined Adductor Canal Block and Selective Tibial Nerve Block (ACB + STNB) Type: Procedure~Description:~Participants receive an ultrasound-guided adductor canal block followed by a selective tibial nerve block.~Dose and Administration:~Adductor Canal Block (ACB): 20 ml of 0.25% bupivacaine. Selective Tibial Nerve Block (STNB): 20 ml of 0.25% bupivacaine. Objective: To provide comprehensive analgesia to both the anterior and posterior aspects of the knee, aiming to enhance pain relief and reduce opioid consumption.
Study: NCT04937179

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Ischemic Conditioning Low - Sham Comparator
Description: The use of a Hokanson rapid inflator cuff to restrict blood flow at 25mmHg for 5 minutes followed by a 5 minute reperfusion period, repeated for 5 cycles.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ischemic Conditioning High - Active Comparator
Description: The use of a Hokanson rapid inflator cuff to restrict blood flow at 225mmHg for 5 minutes followed by a 5 minute reperfusion period, repeated for 5 cycles.
Study: NCT04843046

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Description: All participants will receive evidence-based individual Cognitive Behavioral Therapy (CBT) shown to be an effective intervention for maintaining abstinence following detoxification. Trained masters-level licensed professional counselors will deliver CBT.
Study: NCT06342791

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laser acupuncture
Description: laser use to stimulate acupuncture points

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: laser acupuncture
Description: laser use to stimulate acupuncture points
Study: NCT06384534

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 6-minute walk distance (6MWD) test on ambient air
Description: 6-minute walk distance (6MWD) test will be performed on ambient air according to clinical standards

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 6-minute walk distance test with supplemental oxygen
Description: 6-minute walk distance (6MWD) test will be performed according to clinical standards additionally with supplemental oxygen therapy (approximately 3l/min, nasal)
Study: NCT05591547

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT/VMAT-Based Accelerated Partial Breast Irradiation
Description: The lumpectomy bed will receive a total of 26 Gy in 5 fractions, with 1 fraction delivered per day. Ideally, the course of radiation therapy would be completed over 5 consecutive treatment days. Treatment must begin within 12 weeks of lumpectomy or re-excision of surgical margins and must be completed within 10 calendar days.
Study: NCT06565377

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimodal biopsychosocial teleprehabilitation
Description: Multimodal biopsychosocial teleprehabilitation containing (pain science and lifestyle) education, stress management and physical activity promotion, guided by shared decision making, motivational interviewing and solution focused therapy principles.~Format: 4 preoperative and 1 postoperative one-on-one (tele-)conferencing sessions with a physical therapist, supplemented by an informational booklet.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best-evidence prehabilitation advice
Description: Best-evidence prehabilitation advice in accordance with the NICE guideline on Joint Replacement (Primary): hip, knee and shoulder (2020), by means of an informational booklet.
Study: NCT06128278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-equol
Description: Oral supplementation of S-equol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-equol
Description: Oral supplementation of S-equol
Study: NCT04574037

Intervention type: OTHER
Intervention: Clinical scores such as SAFE score, NIHSS; demographic data such as age and electrophysiological data (such as the absence/presence of Motor evoked potential)
Description: Clinical scores such as SAFE score, NIHSS; demographic data such as age and electrophysiological data (such as the absence/presence of Motor evoked potential) will determine the predictive functional outcome of the upper limb deficit according to the PREP2 algorithm.
Study: NCT06279273

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: Participants were treated for a total of 20 sessions with active or sham stimulation at 2 mA. Each session lasted 20 min at a fixed daytime interval.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: Participants were treated for a total of 20 sessions with active or sham stimulation at 2 mA. Each session lasted 20 min at a fixed daytime interval.
Study: NCT04914559

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral nutrition supplement - control
Description: Drink 1 cup of liquid nutrition product that contains protein, carbohydrate and fat intended for use as supplemental nutrition.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral nutrition supplement - test
Description: Drink 1 cup of liquid nutrition product that contains protein, carbohydrate and fat designed for people living with diabetes and intended for use as supplemental nutrition.
Study: NCT06443528

Intervention type: DIAGNOSTIC_TEST
Intervention: lung ultrasound
Description: All enrolled infants underwent LUS examination performed by two ultrasound physicians. Monitoring included a complete lung scan in the first 24 hours of life (T0) and at day 3 (T1). All neonates underwent weekly ultrasound examinations until 36 weeks postmenstrual age (T2, T3...), so that the T2 scan was carried out at the end of the first week of life. LUS was performed according to a standardized protocol \[13\] when the neonate was in a quiet state, during routine clinical care to minimise discomfort. All ultrasound images and videos were digitally recorded, anonymised, and reviewed by a senior independent ultrasonographer blinded to patients' clinical information. Each lung was divided into three regions according to the anterior and posterior axillary lines and the mammary line. The regions were the upper-anterior, lower-anterior, and latera regions.
Study: NCT06647940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orelabrutinib Oral Tablet
Description: Orelabrutinib (150 mg po D1-D21) is added from the second cycle of R-CHOP regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-CHOP Protocol
Description: Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone
Study: NCT06650319

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: intravenous LY-M003
Description: The study was a single intravenous infusion of LY-M003 at a rate of 1 mL per minute.
Study: NCT06649617

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Group (Standard Procedure)
Description: Before the application of nursing interventions ( Intramuscular , Intravenous , Subcutaneous Injection) to the patients, the patients' physiological parameters (fever, pulse, blood pressure, respiration and oxygen saturation ), pain levels with VAS and anxiety levels with State- Trait Anxiety Scale were evaluated. Then , information was given about the nursing intervention to be performed as a standard procedure . The nursing intervention was applied. After the application, the patients' physiological parameters (fever, pulse, blood pressure, respiration and oxygen saturation ), pain levels with VAS and anxiety levels with State- Trait Anxiety Scale were evaluated. Whichever nursing intervention was necessary for the patients ( Intramuscular , Intravenous , Subcutaneous Injection), that application was applied. No unnecessary procedure was applied. .

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Therapy Group
Description: Before the application of nursing interventions ( intramuscular , intravenous , subcutaneous injection) to the patients, the patients' physiological parameters (fever, pulse, blood pressure, respiration and oxygen saturation ), pain levels with VAS and anxiety levels with State -Trait Anxiety Scale were evaluated. During the nursing intervention, the patients were made to listen to Büzürk makam, a Turkish musical makam. After the application, the patients' physiological parameters (fever, pulse, blood pressure, respiration and oxygen saturation ), pain levels with VAS and anxiety levels with State -Trait Anxiety Scale were evaluated. Whichever nursing intervention was necessary ( intramuscular , intravenous , subcutaneous injection), that application was performed on the patients . No unnecessary procedure was performed.
Study: NCT05650112

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FB-001
Description: FB-001 is formulated as a powder in capsule intended for oral administration
Study: NCT06649617

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Group
Description: Before the application of nursing interventions ( Intamuscular , Intravenous , Subcutaneous Injection) to the patients, the patients' physiological parameters (fever, pulse, blood pressure, respiration and oxygen saturation ), pain levels with VAS and anxiety levels with State -Trait Anxiety Scale were evaluated. During the nursing intervention, the patients watched 3D videos with relaxation effect with virtual glasses. After the application, the patients' physiological parameters (fever, pulse, blood pressure, respiration and oxygen saturation ), pain levels with VAS and anxiety levels with State -Trait Anxiety Scale were evaluated. Whichever nursing intervention was necessary ( Intamuscular , Intravenous , Subcutaneous Injection), that application was performed on the patients . No unnecessary procedure was performed.
Study: NCT05650112

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FB-001
Description: FB-001 is formulated as a powder in capsule intended for oral administration

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In order to maintain study blinding, matching placebo in identical packaging is manufactured using an inactive powder in capsule
Study: NCT05119556

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Video Telehealth Pulmonary Rehabilitation
Description: Participant will be asked to exercise 3 times a week at their home for 60 minutes each session, via live two-way videoconferencing using a data-enabled smart phone or similar device. A total of 36 sessions will be administered over 13 weeks post-discharge. Sessions will be administered by exercise physiologists located at the University of Alabama at Birmingham. Each session will be scheduled with up to three other participants at a time to mimic group sessions as delivered at center-based pulmonary rehabilitation programs. Exercise sessions will include aerobics, strength or resistance training, breathing exercises, and education sessions. The exercise plans will be tailored according to the participants' baseline exercise tolerance as determined by an initial six minute walk test and their answers to the questionnaires at the baseline visit.
Study: NCT05097261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Racemic ketamine® will be administered by continuous infusion in a prefilled 50 ml syringe at a concentration of 50 mg/ml, undiluted. The ketamine dose is 1 mg/kg/h, to a maximum dose of 120 mg/hour, which corresponds to an infusion rate of 0.02 ml/kg/h to a maximum rate of 2.4 ml/h.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo (NaCl 0.9%) will be provided in the same type syringes and administered at the same infusion rate as the IMP (0.02 ml/kg/h to a maximum rate of 2.4 ml/h).
Study: NCT05855967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: Administered SC
Study: NCT06651710

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Zynamite
Description: Two doses of Mangifera indica leaf extract in its soluble form, Zynamite® S, 100 mg of which 60 mg is mangiferin and 150 mg of which 90 mg is mangiferin, will be tested against a placebo. On the day of the test, the supplements will be administered 30 minutes before the start of the test. The supplements or placebo will be administered in cellulose capsules or similar and accompanied by a glass of water.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Zynamite
Description: Two doses of Mangifera indica leaf extract in its soluble form, Zynamite® S, 100 mg of which 60 mg is mangiferin and 150 mg of which 90 mg is mangiferin, will be tested against a placebo. On the day of the test, the supplements will be administered 30 minutes before the start of the test. The supplements or placebo will be administered in cellulose capsules or similar and accompanied by a glass of water.
Study: NCT06650670

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dietary Supplement: Placebo
Description: Each participant will consume 2 capsules per day in one of the main meals without any restriction in the diet or in their life habits

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Supplement: EPP
Description: Each participant will consume 2 capsules per day in one of the main meals without any restriction in the diet or in their life habits
Study: NCT04843046

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Description: All participants will receive evidence-based individual Cognitive Behavioral Therapy (CBT) shown to be an effective intervention for maintaining abstinence following detoxification. Trained masters-level licensed professional counselors will deliver CBT.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Pioglitazone capsules will start at 30 mg (Detox days 3 and 4) and increase to fixed dose of 45 mg for study weeks 1-12 and will also contain riboflavin.
Study: NCT06650839

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIUT
Description: Treatment of moderate aortic stenosis using non-invasive ultrasound therapy delivered by Valvosoft